InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa
05 janv. 2022 07h30 HE
|
InflaRx N.V.
Phase III study to include a new primary endpoint, the modified HiSCRNew primary endpoint and Phase III trial design to be discussed in detail at virtual R&D event on February 3rdPhase III program...
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)
15 nov. 2021 07h30 HE
|
InflaRx N.V.
Proof of concept established for potential of vilobelimab to reduce use of corticosteroids in AAV patients: vilobelimab demonstrated comparable efficacy to standard of careUse of vilobelimab instead...
InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference
11 nov. 2021 07h30 HE
|
InflaRx N.V.
JENA, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports Third Quarter 2021 Financial & Operating Results
05 nov. 2021 07h30 HE
|
InflaRx N.V.
Feedback received from FDA supportive of new primary endpoint measuring reductions in all three inflammatory Hidradenitis Suppurativa (HS) lesions for Phase III program with vilobelimab in HSIn Phase...
InflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference
03 nov. 2021 07h30 HE
|
InflaRx N.V.
JENA, GERMANY, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
27 oct. 2021 07h30 HE
|
InflaRx N.V.
6 out of 7 patients (85.7%) showed clinical remission (PGA score ≤ 1) and closure of target ulcer in the highest dose cohortTreatment was well tolerated; no dose-related adverse events observedFinal...
InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19
19 oct. 2021 07h30 HE
|
InflaRx N.V.
Initial portion of the grant amounts to EUR 25.8 millionRemainder of the grant will be awarded in three additional milestone-dependent tranches JENA, Germany, Oct. 19, 2021 (GLOBE NEWSWIRE) --...
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
12 oct. 2021 07h30 HE
|
InflaRx N.V.
Study has enrolled 369 patients across 9 countriesTopline results expected to be available in Q1 2022 JENA, Germany, Oct. 12, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage...
InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09 sept. 2021 07h30 HE
|
InflaRx N.V.
JENA, Germany, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint
08 sept. 2021 07h30 HE
|
InflaRx N.V.
InflaRx received feedback from FDA within its Type A meeting which is supportive of a new primary endpoint measuring reductions in all three inflammatory HS lesions – including reductions of draining...